Role of siravyadha in gridhrasi (sciatica): A pilot study

In our daily therapeutic practise, vitavyadhi is one of the most common health issues, and gridhra is one of them. It is characterised by discomfort in the buttock, thigh, leg, or foot that is searing, stinging, or numbing. Low back discomfort may or may not be related to it. Gridhrasi appears to affect both the sedentary and physically demanding patient types. Siravyadha is stated in the Chikitsasutra of Gridhrasi by CharyaCharaka, Sushruta, VagbhattaYogratnakara, and Bhela. A proper siravyadha manifests as lightness in the painful areas of the body, a decrease in pain, a lessening in vyadhi intensity, and a joyful disposition. Siravyadha is typically performed when a disease has a prominently painful symptom. A study was created to assess the effectiveness of siravyadha in Gridharasi. The goal of the study was to determine how well Siravyadha managed the symptoms of Gridhrasi. 10 patients with symptoms of Gridhrasi and fit for Siravyadha were chosen. Siravydha was performed after dravasnigdhayavagupana along with sthanikasnehana and swedana were incorporated and samyakstravitlakshanas were observed. The patient data was evaluated before the siravyadha procedure, immediately after the procedure and on 10th day as a follow up routine. The findings were statistically tabulated using paired ‘t’ test

The Combined Effect of Encapsulating Curcumin and C6 Ceramide in Liposomal Nanoparticles against Osteosarcoma

This study examines the antitumor potential of curcumin and C6 ceramide (C6) against osteosarcoma (OS) cell lines when both are encapsulated in the bilayer of liposomal nanoparticles. Three liposomal formulations were prepared: curcumin liposomes, C6 liposomes and C6-curcumin liposomes. Curcumin in combination with C6 showed 1.5 times enhanced cytotoxic effect in the case of MG-63 and KHOS OS cell lines, in comparison with curcumin liposomes alone. Importantly, C6-curcumin liposomes were found to be less toxic on untransformed primary human cells (human mesenchymal stem cells) in comparison to OS cell lines. In addition, cell cycle assays on a KHOS cell line after treatment revealed that curcumin only liposomes induced G₂/M arrest by upregulation of cyclin B1, while C6 only liposomes induced G₁ arrest by downregulation of cyclin D1. C6-curcumin liposomes induced G₂/M arrest and showed a combined effect in the expression levels of cyclin D1 and cyclin B1. The efficiency of the preparations was tested <i>in vivo</i> using a human osteosarcoma xenograft assay. Using pegylated liposomes to increase the plasma half-life and tagging with folate (FA) for targeted delivery <i>in vivo</i>, a significant reduction in tumor size was observed with C6-curcumin-FA liposomes. The encapsulation of two water insoluble drugs, curcumin and C6, in the lipid bilayer of liposomes enhances the cytotoxic effect and validates the potential of combined drug therapy